ArticleCase reports in endocrinology2026
Unilateral Graves' Disease Developing During Treatment With Tirzepatide in a Patient With Diabetes: A Case Report.
Article in Case reports in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unilateral Graves' Disease Developing During Treatment With Tirzepatide in a Patient With Diabetes: A Case Report.Case reports in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor, demonstrates significant efficacy in lowering blood glucose levels and reducing body weight. Consequently, its use has increased among patients with type 2 diabetes and obesity. Gastrointestinal symptoms are commonly recognized as adverse effects of tirzepatide, while other adverse effects, such as thyroid abnormalities, are rare. This report describes a rare case of unilateral Graves' disease that developed during treatment with tirzepatide. Case Presentation: A 59-year-old woman with type 2 diabetes was treated with tirzepatide resulting in marked glycemic improvement and weight loss. During treatment, she developed fatigue and palpitations, initially attributed to the effects of the drug. Further evaluation revealed thyrotoxicosis with suppressed thyroid-stimulating hormone (TSH), elevated free thyroid hormones, and positive autoantibodies. Imaging revealed increased vascularity and technetium-99 m uptake confined to the right thyroid lobe, consistent with unilateral Graves' disease. The patient's clinical symptoms and thyroid function rapidly improved after initiating antithyroid medications. Conclusions: Although a causal relationship between tirzepatide and the development of Graves' disease cannot be established, this case highlights the difficulty of recognizing hyperthyroidism during potent glucose-lowering therapy. Thus, thyroid function testing should be considered in patients with type 2 diabetes who experience symptoms such as fatigue or palpitations during treatment with tirzepatide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.